1. Home
  2. TYGO vs RCEL Comparison

TYGO vs RCEL Comparison

Compare TYGO & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tigo Energy Inc.

TYGO

Tigo Energy Inc.

HOLD

Current Price

$1.51

Market Cap

116.0M

Sector

Technology

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$3.47

Market Cap

102.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYGO
RCEL
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.0M
102.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TYGO
RCEL
Price
$1.51
$3.47
Analyst Decision
Strong Buy
Buy
Analyst Count
1
4
Target Price
$6.00
$8.67
AVG Volume (30 Days)
394.1K
194.8K
Earning Date
02-10-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$90,781,000.00
$72,401,000.00
Revenue This Year
$95.54
$13.12
Revenue Next Year
$21.30
$27.56
P/E Ratio
N/A
N/A
Revenue Growth
97.41
20.59
52 Week Low
$0.58
$3.25
52 Week High
$4.50
$14.16

Technical Indicators

Market Signals
Indicator
TYGO
RCEL
Relative Strength Index (RSI) 42.19 41.31
Support Level $1.35 $3.30
Resistance Level $1.73 $3.71
Average True Range (ATR) 0.11 0.18
MACD 0.01 0.03
Stochastic Oscillator 38.16 34.78

Price Performance

Historical Comparison
TYGO
RCEL

About TYGO Tigo Energy Inc.

Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: